U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. DDT COA #000027: A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF)
  1. Drugs

DDT COA #000027: A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Drug Evaluation (ODE) II
Division of Pulmonary, Allergy, and Rheumatology Products (DPARP)

DDT COA Number
DDT COA #000027

Instrument Name
A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF)

Disease/Condition
Idiopathic pulmonary fibrosis (IPF)

Concept of Interest
Symptom experience, daily functioning and other health-related quality of life impacts

Context of Use
Adult patients (>18 years) with IPF

COA Type
PRO

Qualification Stage
In transition to 507 process 

Requestor(s)
National Jewish Health

Contact(s)
Jeff Swigris

Date Accepted into CDER’s COA Qualification Program
January 25, 2012

Back to Clinical Outcome Assessments (COA) Qualification Submission

Back to Top